Tumors

DSPE-PEG5000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG5000-KAA can be used for drug delivery.

DSPE-PEG2000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG2000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.

DSPE-PEG1000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG1000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.

DSPE-PEG1000-iRGD is a PEG compound which composed of DSPE and an αv-integrins targeting peptide (iRGD). iRGD peptide binds to αv-integrins, and then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. DSPE-PEG1000-iRGD can be used for drug delivery.

DSPE-PEG5000-ESBP is a PEG compound which composed of DSPE and a E-selectin-binding peptide (ESBP). As a tumor-targeting peptide, ESBP can specifically recognize and bind to receptors or markers on the surface of tumor cells.

DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG2000-K237 can be used for drug delivery.

DSPE-PEG3400-TAASGVRSMH is a PEG compound which composed of DSPE and TAASGVRSMH. TAASGVRSMH has a strong affinity for the NG2 proteoglycan on the PC membrane. DSPE-PEG3400-TAASGVRSMH can be used for drug delivery.

DSPE-PEG5000-ANG is a PEG compound which composed of DSPE and a dual-targeting ligand (Angiopep-2, ANG). ANG exhibits high LRP1 binding efficiency and has been used for glioma-targeting delivery. DSPE-PEG5000-ANG can be used for drug delivery.

DSPE-PEG5000-CGKRK is a PEG compound which composed of DSPE and a cell-penetrating peptide (CGKRK). DSPE-PEG5000-CGKRK can be used for drug delivery.

DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery.

DSPE-PEG5000-Mal-CLPLIPTHIISFS is a PEG compound composed of DSPE and the liver cancer targeting peptide SP94 (HY-P11050A) (sequence SFSIIHTPILPL). SP94 exhibits specific binding to hepatocellular carcinoma (HCC) cells. DSPE-PEG5000-Mal-CLPLIPTHIISFS can be used to prepare lipid nanoparticles to form liver cancer-targeting nanocarriers.

DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery.

DSPE-PEG1000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG1000-YIGSR can be used for drug delivery.

DSPE-PEG1000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. DSPE-PEG1000-K237 can be used for drug delivery.

DSPE-PEG1000-GE11 is a PEG compound which composed of DSPE and an EGFR targeting peptide (GE11). GE11 can be used for EGFR overexpressed cancer cells. DSPE-PEG1000-GE11 can be used for drug delivery.

DSPE-PEG1000-LTLRWVGLMS is a PEG compound which composed of DSPE and a decapeptide (LTLRWVGLMS). The chondroitin sulfate proteoglygan NG2 is a receptor for LTLRWVGLMS. LLRWVGLMS shows the homing of pericytes associated with tumor blood vessels. DSPE-PEG1000-LTLRWVGLMS can be used for drug delivery.

DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery.

DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery.

DSPE-PEG1000-F3 is a PEG compound which composed of DSPE and a nucleolin targeting peptide (F3). F3 peptide can specifically bind to cell surface nucleolin and undergo an effective cell surface to nucleus transport. DSPE-PEG1000-F3 can be used for drug delivery.

DSPE-PEG5000-YIGSR is a PEG compound which composed of DSPE and a biomimetic peptide YIGSR. YIGSR interacts with the 67 kDa laminin binding protein (LBP) and promotes adhesion and spreading of a large number of cell types including endothelial cells, fibroblasts and smooth muscle cells. DSPE-PEG5000-YIGSR can be used for drug delivery.